151 related articles for article (PubMed ID: 38074412)
1. Drug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for β-thalassemia.
Whitney D; Shestopalov I; Fincker M; d'Anjou M; Kral K; Gayron M; Pierciey FJ; Colvin RA
Mol Ther Methods Clin Dev; 2023 Dec; 31():101155. PubMed ID: 38074412
[No Abstract] [Full Text] [Related]
2. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
Thompson AA; Walters MC; Kwiatkowski J; Rasko JEJ; Ribeil JA; Hongeng S; Magrin E; Schiller GJ; Payen E; Semeraro M; Moshous D; Lefrere F; Puy H; Bourget P; Magnani A; Caccavelli L; Diana JS; Suarez F; Monpoux F; Brousse V; Poirot C; Brouzes C; Meritet JF; Pondarré C; Beuzard Y; Chrétien S; Lefebvre T; Teachey DT; Anurathapan U; Ho PJ; von Kalle C; Kletzel M; Vichinsky E; Soni S; Veres G; Negre O; Ross RW; Davidson D; Petrusich A; Sandler L; Asmal M; Hermine O; De Montalembert M; Hacein-Bey-Abina S; Blanche S; Leboulch P; Cavazzana M
N Engl J Med; 2018 Apr; 378(16):1479-1493. PubMed ID: 29669226
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia.
Kansal AR; Reifsnider OS; Brand SB; Hawkins N; Coughlan A; Li S; Cragin L; Paramore C; Dietz AC; Caro JJ
J Mark Access Health Policy; 2021 Jun; 9(1):1922028. PubMed ID: 34178295
[No Abstract] [Full Text] [Related]
5. Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia.
Hongeng S; Anurathapan U; Songdej D; Phuphuakrat A; Jongrak K; Parsons G; Deary B; Bonner M; Veres G; Asmal M
Blood Adv; 2021 Jul; 5(13):2701-2706. PubMed ID: 34196676
[TBL] [Abstract][Full Text] [Related]
6. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
7. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies.
Taher AT; Bou-Fakhredin R; Kattamis A; Viprakasit V; Cappellini MD
Expert Rev Hematol; 2021 Oct; 14(10):897-909. PubMed ID: 34493145
[TBL] [Abstract][Full Text] [Related]
8. Zynteglo: Betibeglogene autotemcel - An innovative therapy for β- thalassemia patients.
Asghar AA; Khabir Y; Hashmi MR
Ann Med Surg (Lond); 2022 Oct; 82():104624. PubMed ID: 36268391
[No Abstract] [Full Text] [Related]
9. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
10. Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients.
Ouyang W; Dong G; Zhao W; Li J; Zhou Z; Yang G; Liu R; Li Y; Zhang Q; Du X; Sun H; Gu Y; Lai Y; Liu S; Liu C
Hum Gene Ther; 2021 May; 32(9-10):481-494. PubMed ID: 33256481
[TBL] [Abstract][Full Text] [Related]
11. Cell-Based Gene Therapy for b-Thalassemia.
Arya Y; Sahi PK
Indian Pediatr; 2023 Apr; 60(4):313-316. PubMed ID: 37002845
[TBL] [Abstract][Full Text] [Related]
12. The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia.
Lancaster V; Richardson M; Beaudoin FL; Synnott PG; Rind DM; Herce-Hagiwara B; Campbell JD; Pearson SD
J Manag Care Spec Pharm; 2022 Nov; 28(11):1316-1320. PubMed ID: 36282936
[No Abstract] [Full Text] [Related]
13. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
Kanter J; Thompson AA; Pierciey FJ; Hsieh M; Uchida N; Leboulch P; Schmidt M; Bonner M; Guo R; Miller A; Ribeil JA; Davidson D; Asmal M; Walters MC; Tisdale JF
Am J Hematol; 2023 Jan; 98(1):11-22. PubMed ID: 36161320
[TBL] [Abstract][Full Text] [Related]
14. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
Kanter J; Walters MC; Krishnamurti L; Mapara MY; Kwiatkowski JL; Rifkin-Zenenberg S; Aygun B; Kasow KA; Pierciey FJ; Bonner M; Miller A; Zhang X; Lynch J; Kim D; Ribeil JA; Asmal M; Goyal S; Thompson AA; Tisdale JF
N Engl J Med; 2022 Feb; 386(7):617-628. PubMed ID: 34898139
[TBL] [Abstract][Full Text] [Related]
15. Case study of betibeglogene autotemcel gene therapy in an adult Greek patient with transfusion-dependent β-thalassaemia of a severe genotype.
Constantinou V; Papayanni PG; Mallouri D; Batsis I; Bouinta A; Papadopoulou D; Papadimitriou V; Kammenou M; Pantelidou D; Sotiropoulos D; Sakellari I; Anagnostopoulos A; Yannaki E
Br J Haematol; 2022 Mar; 196(6):1401-1404. PubMed ID: 34957544
[No Abstract] [Full Text] [Related]
16. Betibeglogene Autotemcel; A New Hope For Transfusion Dependent Beta-Thalassaemia.
Wally HT; Zulfi MH; Jilani ES
J Pak Med Assoc; 2023 Oct; 73(10):2129-2130. PubMed ID: 37876093
[No Abstract] [Full Text] [Related]
17. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia.
Marktel S; Scaramuzza S; Cicalese MP; Giglio F; Galimberti S; Lidonnici MR; Calbi V; Assanelli A; Bernardo ME; Rossi C; Calabria A; Milani R; Gattillo S; Benedicenti F; Spinozzi G; Aprile A; Bergami A; Casiraghi M; Consiglieri G; Masera N; D'Angelo E; Mirra N; Origa R; Tartaglione I; Perrotta S; Winter R; Coppola M; Viarengo G; Santoleri L; Graziadei G; Gabaldo M; Valsecchi MG; Montini E; Naldini L; Cappellini MD; Ciceri F; Aiuti A; Ferrari G
Nat Med; 2019 Feb; 25(2):234-241. PubMed ID: 30664781
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.
Magrin E; Semeraro M; Hebert N; Joseph L; Magnani A; Chalumeau A; Gabrion A; Roudaut C; Marouene J; Lefrere F; Diana JS; Denis A; Neven B; Funck-Brentano I; Negre O; Renolleau S; Brousse V; Kiger L; Touzot F; Poirot C; Bourget P; El Nemer W; Blanche S; Tréluyer JM; Asmal M; Walls C; Beuzard Y; Schmidt M; Hacein-Bey-Abina S; Asnafi V; Guichard I; Poirée M; Monpoux F; Touraine P; Brouzes C; de Montalembert M; Payen E; Six E; Ribeil JA; Miccio A; Bartolucci P; Leboulch P; Cavazzana M
Nat Med; 2022 Jan; 28(1):81-88. PubMed ID: 35075288
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
20. Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy.
Jang Y; Kim YS; Wielgosz MM; Ferrara F; Ma Z; Condori J; Palmer LE; Zhao X; Kang G; Rawlings DJ; Zhou S; Ryu BY
Gene Ther; 2020 Dec; 27(12):545-556. PubMed ID: 32341484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
